| SAINT LOUIS UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120083443 | Control of ATP Release by Red Blood Cells and Therapeutic Applications Thereof - The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCS treated with insulin accumulate significantly less cAMP and release significantly less ATP than normal RBCS. Likewise, RBCS of patients suffering from type 2 diabetes (hyperinsulinemia) accumulate significantly less cAMP and release significantly less ATP than normal RBCS. It was further discovered that prostaglandin analogues synergistically work with phosphodiesterase 3B inhibitors to improve or increase cAMP accumulation and ATP release RBCS. Thus the invention is directed to compositions and methods for improving ATP release by RBCS, via administering PDE3B inhibitor or a combination of PDE3B inhibitor and prostaglandin analogue. | 04-05-2012 |
| 20120077218 | SICKLE CONFIRM MODIFIED HEMOGLOBIN SOLUBILITY TEST - The present invention provides a method for determining sickle-cell zygosity in a subject, comprising: forming a first solution comprising a sample from the subject, a phosphate buffer, a detergent, and a reducing agent; subjecting the first solution to centrifugation to form a second solution and a supernatant; taking a color reading of the supernatant and of the second solution; optionally filtering the second solution to form a filtrate and a precipitate, and optionally measuring the amount of the precipitation and the absorbance of the filtrate or taking a color reading of the filtrate. | 03-29-2012 |
| 20120028242 | BIOSENSOR FOR DETECTING MULTIPLE EPITOPES ON A TARGET - The present invention encompasses a method for detecting a target comprising a repeating epitope. | 02-02-2012 |
| 20120027526 | METHOD AND STRUCTURE FOR REDUCING TURBULENCE AROUND AND EROSION OF UNDERWATER STRUCTURES - An underwater structure for supporting an above-water structure having an underwater portion immersed for some period of time underneath a water line of a body of water is provided. The underwater structure includes, but is not limited to, a turbulence reducing member connected with the underwater portion. | 02-02-2012 |
| 20120021416 | BIOLAYER INTERFEROMETRY MEASUREMENT OF BIOLOGICAL TARGETS - Disclosed are methods and compositions for the ultrasensitive detection of oligonucleotides, proteins, protein complexes, biomolecules, and infectious agents using a peroxidase driven deposition of substrates onto interferometry capable biosensors, coupled to the specific recognition of the target molecules. More specifically, methods are disclosed to specifically immobilize biological target molecules onto the surface of interferometry capable biosensors and to associate the target molecules with peroxidase enzymes. Through the peroxidase driven deposition of substrates onto the interferometry capable biosensors there is the ability to achieve ultrasensitive detection and quantification of specific target molecules. | 01-26-2012 |
| 20120005765 | ANIMAL MODEL FOR PARKINSON'S DISEASE - Disclosed are methods and compositions for an animal model of Parkinson's disease. In particular, disclosed is the use of antisense compounds to inhibit the expression of ALDH1A1 in the substantia nigra of an animal brain for the purpose of creating an animal that will displays the symptoms of a human with Parkinson's Disease, including various biochemical, histological, and behavioral characteristics. Also disclosed are methods for using the animal model for Parkinson's disease to test potential therapeutic agents for Parkinson's disease. | 01-05-2012 |
| 20110311487 | DELIVERY OF THERAPEUTIC AGENTS TO THE BONE - This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector. | 12-22-2011 |
| 20110300143 | PRENATAL ENZYME REPLACEMENT THERAPY - The invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy. The fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion. | 12-08-2011 |
| 20110288598 | LOCKING SCREW DEVICE - Locking screw system includes screw and female threaded receiver that provide for and lock through interference fitting, which may be from major-major and/or minor-minor diameter interference. The system may be embodied as an orthopedic implant or implant component. | 11-24-2011 |
| 20110281933 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF CARDIOVASCULAR DISEASE WITH OLIGONUCLEOTIDES - Disclosed are compositions and methods for treating cardiovascular disease and reducing the adverse effects induced by the administration of statins. In particular, disclosed is the use of antisense compounds to augment the expression of mirR-33 and associated genetic elements. In particular methods of the treatment of cardiovascular disease and the modulation of miR-33 levels is disclosed as well as treatment of the secondary effects including cholestasis, induced by the administration of statins is disclosed. Also disclosed is the treatment of Benign Recurrent Intrahepatic Cholestasis and reverse cholesterol transport. The disclosed methods and compositions may be practiced separately or co-administered with satins to reduce or treat statin induced secondary effects. | 11-17-2011 |
| 20110277890 | METHOD FOR CONTROLLING PHASE TRANSFORMATION TEMPERATURE IN METAL ALLOY OF A DEVICE - An efficient method to reduce product wastes due to inaccurate transformation temperatures for shape memory products and parts, which provides a useful method for optimizing shape memory alloys phase transformation temperatures and mechanical properties by using heat treatment procedures below 250 degrees C. for extended dwell times. | 11-17-2011 |
| 20110256563 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody. | 10-20-2011 |
| 20110250187 | COMPOSITIONS AND METHODS FOR TREATING HYPOPHOSPHATASIA - The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue. | 10-13-2011 |
| 20110091980 | DIAGNOSTIC METHOD FOR BIOMARKERS OF ADVERSE CORONARY EVENTS - A diagnostic method using biomarkers to predict future adverse coronary events is provided. More particularly, the present invention is directed to diagnostic tests for characterizing an individual's risk of developing or having cardiovascular disease. In certain embodiments, the method of the present invention quantitates the presence of elevated levels of chlorinated lipids derived from myeloperoxidase as a prognostic indicator of future adverse coronary events. | 04-21-2011 |
| 20110091893 | BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides molecular biosensors. In particular, the invention provides molecular biosensors having one or more aptamers. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 04-21-2011 |
| 20110076297 | Peptides for Inducing Heterosubtypic Influenza T Cell Responses - The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infaction also are described. | 03-31-2011 |
| 20110014275 | COMPOSITIONS AND METHODS FOR INHIBITING OR INDUCING ADIPOGENESIS - This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPARγ, and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPARγ, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis. | 01-20-2011 |
| 20100297654 | THREE-COMPONENT BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 11-25-2010 |
| 20100247511 | METHODS AND COMPOSITIONS FOR ACTIVATED PROTEIN C WITH REDUCED ANTICOAGULANT PROPERTIES - This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding. | 09-30-2010 |
| 20100241120 | INTRAMEDULLARY NAIL DEVICE AND METHOD FOR REPAIRING LONG BONE - The present invention describes a intramedullary nail that is useful in the repair of long bone fractures, wherein the nail has a flexible state, which allows for the insertion of the nail through any number of incisions that may be off center of the intramedullary canal, and a rigid state, which allows the nail to provide adequate support to mend the long bone. Several embodiments of an intramedullary nail are described, including a nail comprising a shape memory nickel-titanium alloy, which has an austenite start temperature of about 15° C. and an austenite finish temperature of about 35° C., and a nail comprising loosely fitting multiple links that can be tightened to provide rigidity when properly set in the intramedullary canal. | 09-23-2010 |
| 20100202869 | HUBLESS WINDMILL - Systems, apparatus and methods for generating power from fluid motion, such as wind are provided. The apparatus is a wing-shaped airfoil with cup-shaped indentations that allow the airfoil to harness wind energy throughout a wide range of wind speeds and from different wind directions. The indentations harness wind energy at low wind speeds while the wing-shape generates a lifting force at high wind speeds to harness wind energy. The system comprises one or more of the devices configured in a hollow, generally cylindrical, shape and connected to a ring frame. The system rotates about an axis running through the center of the ring frame. The rotational motion of the system generates electrical power via a generator. The method is a method for generating electrical power from the rotational motion of the system. | 08-12-2010 |
| 20100131202 | APPARATUS AND METHOD FOR PROVIDING ENVIRONMENTAL PREDICTIVE INDICATORS TO EMERGENCY RESPONSE MANAGERS - A method of predicting weather-exacerbated threats, said method comprising inputting localized weather measurement data into a weather threat prediction system; predicting future localized weather conditions based on said localized weather measurement data combined with modeling from National Weather Service Data; inputting natural environment and infrastructure data into said weather threat prediction system; correlating said infrastructure data with said predicted future localized weather conditions; and determining a threat level index over a region, a threat level indicating an area having a certain probabilistic likelihood of being harmed by said future weather conditions. | 05-27-2010 |
| 20100086543 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS - Provided are a pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor and a pharmaceutically acceptable carrier. The method of treatment involves administration of an opioid drug and a ceramide biosynthesis inhibitor. Also provided are a method of screening for an agent that reduces, prevents or delays the development of tolerance to and/or physical dependence on an opioid drug as well as compositions comprising a dsRNA for inhibiting ceramide biosynthesis in a cell and a vector for expressing a shRNA for inhibiting ceramide biosynthesis in a cell. | 04-08-2010 |
| 20100010611 | STENT BASED METHOD AND APPARATUS FOR DIRECTING EXTERNAL BEAM RADIATION THERAPY - A stent based apparatus and method for directing external beam radiation comprising a series of devices and a system of implanting these devices within a patient to direct therapeutic radiation given to the patient. Each of the devices can deliver a tiny gold fiducial (or fiducial constructed of another material capable of acting as a target to direct external beam therapeutic radiation) to a target area in the vicinity of a cancer or other lesion that is considered an appropriate target for external beam radiation therapy, using, for example, the beam radiation system referred to as the Cyberknife radiation delivery system. The current system and devices envision placement of gold fiducials through hollow organs in the body (for example, the gastrointestinal tract, the ureter, blood vessels, bile duct, or the cerebro spinal fluid space). This implantation method can utilize conventional endoscopy or angiography. | 01-14-2010 |
| 20100008979 | DELIVERY OF THERAPEUTIC AGENTS TO THE BONE - This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector. | 01-14-2010 |
| 20090280505 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody. | 11-12-2009 |
| 20090254023 | METHOD AND APPARATUS FOR SUTURELESS INJECTABLE RETINAL DETACHMENT SPONGE IMPLANTATION - A method and apparatus for a suture less injectable retinal detachment sponge and method for placing the sponge in a pocket beneath the surface of the sclera is the subject of the present invention. An exterior accessible pocket can be created in the sclera by making an incision in the outer surface. The incision can be made utilizing a crescent blade. The apparatus used to perform the procedure for insertion of the sponge in the pocket utilizes an injector having a cylinder and plunger combination. The cylinder can have a sponge removably contained therein and a plunger for injecting the sponge out of the cylinder portion of the injector to the desired location within the pocket. | 10-08-2009 |
| 20090238814 | COMPOSITIONS AND METHODS FOR TREATING HYPOPHOSPHATASIA - The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue. | 09-24-2009 |
| 20090208051 | METHOD AND APPARATUS FOR FLUOROGENIC DETERMINATION OF LEAD CONCENTRATIONS - A method and apparatus for the use of fluorogenic probes for development of a rapid, and cost-effective determination of lead clearance following lead hazard control activities. The invention involves the use of fluorogenic chemosensors for efficient detection of lead in dust on hard surfaces at regulatory levels. The use of methods for lead visualization based on one or more of the fluorogenic type compounds would be highly beneficial to lead abatement projects. The identification of areas of high lead concentration (hotspots) can allow work to be focused on areas that have the greatest impact on clearance. Also, a rapid and cost-effective means of determining if lead clearance has been met can improve compliance with lead abatement activities. This would decrease the amount of time and materials spent in general surface cleaning and allow the elimination of isolated areas of lead concentration that may otherwise have been missed. | 08-20-2009 |
| 20090202990 | METHODS FOR THE SELECTION OF APTAMERS - The present invention generally relates to methods for selecting aptamers. More specifically, the invention provides methods for the selection of at least one aptamer for use in combination with another epitope binding agent such as another aptamer, an antibody, or a double stranded nucleic acid. The invention also encompasses methods for simultaneously selecting at least two aptamers that each recognize distinct epitopes on a target molecule. | 08-13-2009 |
| 20090197320 | ANCESTRAL DENGUE VIRUS ENVELOPE PROTEIN - Disclosed is a dengue virus envelope protein sequence derived via ascertainment of a most recent common ancestor of the three dengue serotype variants, DENV-1, DENV-2, DENV-3 and DENV-4. This synthetic dengue virus envelope protein can be used as a tetravalent vaccine in the prevention of dengue fever, dengue hemorrhagic fever and dengue septic shock. | 08-06-2009 |
| 20090148832 | Compositions and Methods for Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes - The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease. | 06-11-2009 |
| 20090087451 | Methods and Compositions for Vaccination - The invention provides kits, methods and compositions of matter which improve the safety of vaccination. By combining the administration of antiviral drugs, particularly ester derivatives of cidofovir, with the administration of viral vaccines, particularly the variola vaccine DryVax, side effects of the vaccine are diminished without significantly affecting the effectiveness of the vaccine. | 04-02-2009 |
| 20090041741 | MODIFIED ENZYME AND TREATMENT METHOD - There is disclosed an isolated, modified recombinant β-glucuronidase wherein the modification is having its carbohydrate moeties chemically modified so as to reduce its activity with respect to mannose and mannose 6-phosphate cellular delivery system while retaining enzymatic activity Also disclosed are methods for the treatment of lysosomal storage disease in mammals wherein the mammal is administered a therapeutically effective amount of isolated, modified recombinant β-glucuronidase whereby said storage diseased is relieved in the brain and visceral organs of the mammal. Also disclosed are other lysosomal enzymes within the scope of the invention. | 02-12-2009 |
| 20090017448 | SCREENING TOOL FOR ANTIVIRAL AGENTS - A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents. | 01-15-2009 |
| 20080318207 | SEQUENCE COVARIANCE NETWORKS, METHODS AND USES THEREFOR - Methods of identifying targets for designing a therapeutic agent are disclosed. These methods comprise: determining an amino acid sequence of one or more polypeptides of each isolate of a plurality of isolates of a biological system; identifying covariance pairs of amino acid residues; establishing a network comprising the covariance pairs; and identifying one or more hub residue positions, wherein a hub residue position comprises a target for designing a therapeutic agent if the hub residue position has a rank order in the 40 | 12-25-2008 |
| 20080234178 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE SYSTEM MEDIATED DISEASES - The present invention is directed to compositions and methods for treating immune system mediated disease. In particular, certain embodiments of the present invention use BH3 mimetic therapy as an efficacious treatment of the effector phase of RA wherein the compositions and methods of the present invention markedly reduce the level of the Bcl-2 antagonist protein Bim present in RA synovial tissue as compared to control patients. Therefore, the present invention involves restoring the function of Bim in order to ameliorate inflammatory arthritis. In connection therewith, systemic delivery of a peptide to the BH3 domain of Bim effectively inhibits the development of K/B×N serum transfer-induced arthritis which closely resembles the effector phase of RA | 09-25-2008 |
